Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study

Table 2

Body weight, waist circumference, and liver biological indicators at different times.

Variable	Metformin				Pioglitazone + metformin
	Baseline	12 weeks	24 weeks	Baseline -24 weeks	Baseline	12 weeks	24 weeks	Baseline -24 weeks
Primary endpoint
γ-GT (IU/L)
C-peptide (mIU/L)
AST (IU/L)
ALT (IU/L)
FINS
Secondary endpoint
LDL-C (mmol/L)
HDL-C (mmol/L)
TC (mmol/L)
TG (mmol/L)
Weight (kg)
Waist circumference (cm)
HbA1c (%)
FBG (mmol/L)
PBG (mmol/L)
IR index
POINS2H (mIU/L)

Note: data are . and compared with the metformin group. Abbreviation: ALT: alanine aminotransferase; AST: aspartate aminotransferase; TG: triglycerides; TC: total cholesterol; HBA1C: glycated hemoglobin; LDL: low-density lipoprotein; HDL: high-density lipoprotein; HBA1C: glycated hemoglobin; POINS2H: postprandial insulin; FBG: fasting blood glucose; FINS: fasting insulin; PBG: 2-hour postprandial blood glucose.